CD8A and neoplasm: A retrospective analysis of the same clinical trial reported that OC tumors with high CD8+ T-cell infiltration (“hot tumors”) with a high tumor mutational burden (TMB), profit more from chemotherapy, while less infiltrated or “cold” tumors with a low TMB rely on moDC vaccination (irrespective of when moDC vaccination was given) to kick-start anti-cancer responses [97].